SC seeks Centre’s reply on plea alleging no approval for Remdesivir, Favipiravir to deal with COVID-19


New Delhi, October 29

The Supreme Court on Thursday sought response from the Centre on a plea alleging that two medicines, Remdesivir and Favipiravir, are being used for the treatment of COVID-19 without approval.

A bench headed by Chief Justice SA Bobde issued notice to the Centre on the plea and sought its response in four weeks.

Advocate ML Sharma, petitioner in-person, referred to the Bench — also comprising Justices AS Bopanna and V Ramasubramanian — the World Health Organisation (WHO) report of October 15 and said nowhere these medicines were designated officially as medicines for coronavirus.

The bench said it was only going to make the Central Government aware of it and, therefore, was issuing a notice.

On September 16, the top court had said there was an approval by the Central Government on use of Remdesivir and Favipiravir as medicines to treat COVID-19.

The top court was hearing a plea seeking the registration of an FIR by the CBI against 10 Indian pharmaceutical firms for manufacturing and selling these two medicines for treating COVID-19 patients allegedly without valid licences.

Remdesivir and Favipiravir are antiviral drugs and their efficacy in treating COVID-19 patients has been a matter of debate among medical experts. PTI



Be the first to comment on "SC seeks Centre’s reply on plea alleging no approval for Remdesivir, Favipiravir to deal with COVID-19"

Leave a comment

Your email address will not be published.


*


%d bloggers like this: